Table 1. Patient, donor, and... | American Society of Hematology

Table 1.

Patient, donor, and transplantation characteristics, N = 96

Characteristic	Value
Age, y, median (SD)	19.4 (12.6)
Sex, male/female, no.	53/43
Primary disease, no.
Hematologic malignancy	50
Acute leukemia	26
Chronic myelogenous leukemia	23
Myeloma	1
Aplastic anemia	40
Other diagnoses*	6
Donor type, no.
HLA-identical sibling	82
Unrelated	14
Conditioning regimen, no.
TBI containing	79
Cyclophosphamide plus TBI with or without other drug	77
Other	2
Non-TBI containing	17
Cyclophosphamide alone	11
Busulfan plus cyclophosphamide	6
GVHD prophylaxis, no.
Cyclosporine alone	25
Methotrexate alone	14
Cyclosporine plus methotrexate with or without other drug	47
Cyclosporine with or without prednisone	3
Other regimen	3
None†	4
HCV genotype, no.
Type 1	35
Type 2	14
Type 3	12
Type 4	4

Characteristic	Value
Age, y, median (SD)	19.4 (12.6)
Sex, male/female, no.	53/43
Primary disease, no.
Hematologic malignancy	50
Acute leukemia	26
Chronic myelogenous leukemia	23
Myeloma	1
Aplastic anemia	40
Other diagnoses*	6
Donor type, no.
HLA-identical sibling	82
Unrelated	14
Conditioning regimen, no.
TBI containing	79
Cyclophosphamide plus TBI with or without other drug	77
Other	2
Non-TBI containing	17
Cyclophosphamide alone	11
Busulfan plus cyclophosphamide	6
GVHD prophylaxis, no.
Cyclosporine alone	25
Methotrexate alone	14
Cyclosporine plus methotrexate with or without other drug	47
Cyclosporine with or without prednisone	3
Other regimen	3
None†	4
HCV genotype, no.
Type 1	35
Type 2	14
Type 3	12
Type 4	4

SD indicates standard deviation; HLA, human leukocyte antigen; and TBI, total body irradiation.

Thalassemia (n = 2), Glanzmann thrombasthenia, Diamond-Blackfan syndrome (n = 2), dyskeratosis congenital.

Transplantation in which the donor and recipient were twins.